gefitinib has been researched along with podophyllotoxin in 5 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (podophyllotoxin) | Trials (podophyllotoxin) | Recent Studies (post-2010) (podophyllotoxin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 3,119 | 226 | 782 |
| Protein | Taxonomy | gefitinib (IC50) | podophyllotoxin (IC50) |
|---|---|---|---|
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | 2.145 | |
| Tubulin alpha-1A chain | Sus scrofa (pig) | 0.6733 | |
| Tubulin beta chain | Sus scrofa (pig) | 0.622 | |
| Glucocorticoid receptor | Homo sapiens (human) | 0.014 | |
| Tubulin beta-4A chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta chain | Homo sapiens (human) | 1.7233 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.6 | |
| Tubulin alpha-3C chain | Homo sapiens (human) | 1.7233 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 4 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 5 | |
| Tubulin alpha-1B chain | Homo sapiens (human) | 1.7233 | |
| Tubulin alpha-4A chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-4B chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-3 chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-2A chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-8 chain | Homo sapiens (human) | 1.7233 | |
| Calcium-activated potassium channel subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.56 | |
| Tubulin beta-2B chain | Bos taurus (cattle) | 0.8685 | |
| Tubulin alpha-3E chain | Homo sapiens (human) | 1.7233 | |
| Tubulin alpha-1A chain | Homo sapiens (human) | 1.7233 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 0.907 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 0.7744 | |
| Tubulin alpha-1C chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-6 chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-2B chain | Homo sapiens (human) | 1.7233 | |
| Tubulin beta-1 chain | Homo sapiens (human) | 1.7233 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Cherpelis, B; Rudnick, EW; Thareja, S | 1 |
| Chae, JI; Cho, SS; Kim, E; Kwak, AW; Lee, MH; Liu, K; Oh, HN; Shim, JH; Yoon, G | 1 |
| Chae, JI; Cho, SS; Kim, E; Kim, HS; Kwak, AW; Lee, MH; Oh, HN; Seo, JH; Shim, JH; Yoon, G | 1 |
1 review(s) available for gefitinib and podophyllotoxin
| Article | Year |
|---|---|
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden | 2016 |
4 other study(ies) available for gefitinib and podophyllotoxin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Targeted inhibition of c-MET by podophyllotoxin promotes caspase-dependent apoptosis and suppresses cell growth in gefitinib-resistant non-small cell lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Targeted Therapy; Podophyllotoxin; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met | 2021 |
Deoxypodophyllotoxin Inhibits Cell Growth and Induces Apoptosis by Blocking EGFR and MET in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Apiaceae; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Podophyllotoxin; Proto-Oncogene Proteins c-met; Signal Transduction | 2021 |